Medical Treatment of Charcot Neuroosteoarthropathy

Clinics in Podiatric Medicine and Surgery

Volumn 25, Issue 1, 2008, Pages 63-69

  Jostel, Andreas ^a   Jude, Edward B ^a  

^a TAMESIDE AND GLOSSOP INTEGRATED CARE NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; ETIDRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; ZOLEDRONIC ACID;

ADJUVANT THERAPY; BONE DENSITY; CHARCOT NEUROOSTEOARTHROPATHY; CLINICAL TRIAL; DIABETIC PATIENT; DRUG INHIBITION; FOLLOW UP; HUMAN; LONG TERM CARE; NEUROPATHIC JOINT DISEASE; OSTEOPOROSIS; PHYSICAL STRESS; PRIORITY JOURNAL; REVIEW; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; VISUAL ANALOG SCALE;

ARTHROPATHY, NEUROGENIC; BONE DENSITY CONSERVATION AGENTS; CYTOKINES; DIPHOSPHONATES; HUMANS; INFLAMMATION; OSTEOCLASTS;

EID: 37349056415     PISSN: 08918422     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cpm.2007.09.001     Document Type: Review

References (27)

1. Hartemann-Heurtier A., Van G.H., and Grimaldi A. The Charcot foot. Lancet 360 9347 (2002) 1776-1779
2. Boulton A.J. The diabetic foot: from art to science. The 18th Camillo Golgi lecture. Diabetologia 47 8 (2004) 1343-1353
3. Jeffcoate W.J., Game F., and Cavanagh P.R. The role of proinflammatory cytokines in the cause of neuropathic osteoarthropathy (acute Charcot foot) in diabetes. Lancet 366 9502 (2005) 2058-2061
4. Baumhauer J.F., O'Keefe R.J., Schon L.C., et al. Cytokine-induced osteoclastic bone resorption in Charcot arthropathy: an immunohistochemical study. Foot Ankle Int 27 10 (2006) 797-800
5. Young M.J., Marshall A., Adams J.E., et al. Osteopenia, neurological dysfunction, and the development of Charcot neuroarthropathy. Diabetes Care 18 1 (1995) 34-38
6. Larsen K., Fabrin J., and Holstein P.E. Incidence and management of ulcers in diabetic Charcot feet. J Wound Care 10 8 (2001) 323-328
7. Herbst S.A., Jones K.B., and Saltzman C.L. Pattern of diabetic neuropathic arthropathy associated with the peripheral bone mineral density. J Bone Joint Surg Br 86 3 (2004) 378-383
8. Tan A.L., Greenstein A., Jarrett S.J., et al. Acute neuropathic joint disease: a medical emergency?. Diabetes Care 28 12 (2005) 2962-2964
9. Chantelau E. The perils of procrastination: effects of early vs. delayed detection and treatment of incipient Charcot fracture. Diabet Med 22 12 (2005) 1707-1712
10. Jude E.B., Selby P.L., Burgess J., et al. Bisphosphonates in the treatment of Charcot neuroarthropathy: a double-blind randomised controlled trial. Diabetologia 44 11 (2001) 2032-2037
11. Sinacore D.R. Acute Charcot arthropathy in patients with diabetes mellitus: healing times by foot location. J Diabetes Complications 12 5 (1998) 287-293
12. Armstrong D.G., Todd W.F., Lavery L.A., et al. The natural history of acute Charcot's arthropathy in a diabetic foot specialty clinic. Diabet Med 14 5 (1997) 357-363
13. Armstrong D.G., Lavery L.A., Kimbriel H.R., et al. Activity patterns of patients with diabetic foot ulceration: patients with active ulceration may not adhere to a standard pressure off-loading regimen. Diabetes Care 26 9 (2003) 2595-2597
14. Armstrong D.G., Short B., Espensen E.H., et al. Technique for fabrication of an "instant total-contact cast" for treatment of neuropathic diabetic foot ulcers. J Am Podiatr Med Assoc 92 7 (2002) 405-408
15. Edelson G.W., Jensen J.L., and Kaczynski R. Identifying acute Charcot arthropathy through urinarycross-linked N-telopeptides. Diabetes 45 Suppl 2 (1996) 108A
16. Gough A., Abraha H., Li F., et al. Measurement of markers of osteoclast and osteoblast activity in patients with acute and chronic diabetic Charcot neuroarthropathy. Diabet Med 14 7 (1997) 527-531
17. Selby P.L., Jude E.B., Burgess J., et al. Bone turnover markers in acute Charcot neuroarthropathy. Diabetologia 41 Suppl 1 (1998) A275
18. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 19 1 (1998) 80-100
19. Zaidi M., Blair H.C., Moonga B.S., et al. Osteoclastogenesis, bone resorption, and osteoclast-based therapeutics. J Bone Miner Res 18 4 (2003) 599-609
20. Green J.R. Bisphosphonates: preclinical review. Oncologist 9 Suppl 4 (2004) 3-13
21. Selby P.L., Young M.J., and Boulton A.J. Bisphosphonates: a new treatment for diabetic Charcot neuroarthropathy?. Diabet Med 11 1 (1994) 28-31
22. Anderson J.J., Woelffer K.E., Holtzman J.J., et al. Bisphosphonates for the treatment of Charcot neuroarthropathy. J Foot Ankle Surg 43 5 (2004) 285-289
23. Pitocco D., Ruotolo V., Caputo S., et al. Six-month treatment with alendronate in acute Charcot neuroarthropathy: a randomized controlled trial. Diabetes Care 28 5 (2005) 1214-1215
24. Zaidi M., Inzerillo A.M., Moonga B.S., et al. Forty years of calcitonin-where are we now? A tribute to the work of Iain Macintyre, FRS. Bone 30 5 (2002) 655-663
25. Bem R., Jirkovska A., Fejfarova V., et al. Intranasal calcitonin in the treatment of acute Charcot neuroosteoarthropathy: a randomized controlled trial. Diabetes Care 29 6 (2006) 1392-1394
26. Simonet W.S., Lacey D.L., Dunstan C.R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89 2 (1997) 309-319
27. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 142 12 (2001) 5050-5055